1. Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2.
- Author
-
Dutta, Ritika, Tian Yi Zhang, Köhnke, Thomas, Thomas, Daniel, Linde, Miles, Gars, Eric, Stafford, Melissa, Kaur, Satinder, Nakauchi, Yusuke, Yin, Raymond, Azizi, Armon, Narla, Anupama, Majeti, Ravindra, and Zhang, Tian Yi
- Subjects
- *
CELL differentiation , *PORPHYRINS , *RESEARCH , *HETEROCYCLIC compounds , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *AMINOPYRIDINES , *CELLS , *RESEARCH funding , *OXIDOREDUCTASES , *HEMATOPOIETIC stem cells , *CHEMICAL inhibitors - Abstract
Cancer-related anemia is present in more than 60% of newly diagnosed cancer patients and is associated with substantial morbidity and high medical costs. Drugs that enhance erythropoiesis are urgently required to decrease transfusion rates and improve quality of life. Clinical studies have observed an unexpected improvement in hemoglobin and RBC transfusion-independence in patients with acute myeloid leukemia (AML) treated with the isocitrate dehydrogenase 2 (IDH2) mutant-specific inhibitor enasidenib, leading to improved quality of life without a reduction in AML disease burden. Here, we demonstrate that enasidenib enhanced human erythroid differentiation of hematopoietic progenitors. The phenomenon was not observed with other IDH1/2 inhibitors and occurred in IDH2-deficient CRISPR-engineered progenitors independently of D-2-hydroxyglutarate. The effect of enasidenib on hematopoietic progenitors was mediated by protoporphyrin accumulation, driving heme production and erythroid differentiation in committed CD71+ progenitors rather than hematopoietic stem cells. Our results position enasidenib as a promising therapeutic agent for improvement of anemia and provide the basis for a clinical trial using enasidenib to decrease transfusion dependence in a wide array of clinical contexts. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF